Breaking News Instant updates and real-time market news.

REGN

Regeneron

$447.15

-5.82 (-1.28%)

, MRK

Merck

09:15
10/13/17
10/13
09:15
10/13/17
09:15

Barclays cautious on Merck and Regeneron into Q3 results

In a research note previewing the Q3 earnings reports for U.S. Biopharmaceuticals, Barclays analyst Geoff Meacham says he's positive on positive on Amgen (AMGN) and Alexion Pharmaceuticals (ALXN), cautious on Merck (MRK), and bearish on Regeneron (REGN). The analyst made a host of price target changes, including raising Amgen's target to $190 from $180, AbbVie's (ABBV) target to $90 from $68 and Bristol-Myers' target to $65 from $58.

REGN

Regeneron

$447.15

-5.82 (-1.28%)

MRK

Merck

AMGN

Amgen

$182.76

-1.39 (-0.75%)

ALXN

Alexion

$141.46

0.23 (0.16%)

ABBV

AbbVie

BMY

Bristol-Myers

  • 15

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 23

    Oct

  • 23

    Oct

  • 26

    Oct

  • 26

    Oct

  • 27

    Oct

  • 27

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 09

    Nov

  • 30

    Nov

  • 02

    Dec

  • 02

    Feb

  • 03

    Feb

  • 05

    Mar

  • 30

    Apr

  • 17

    May

  • 28

    May

REGN Regeneron
$447.15

-5.82 (-1.28%)

09/29/17
09/29/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Regeneron (REGN) assumed with an Overweight at Piper Jaffray. 2. MasterCard (MA) and Visa (V) were initiated with an Overweight at Cantor Fitzgerald. 3. Liberty Global (LBTYA, LBTYK) and Liberty Global LiLAC (LILA) were initiated with a Buy at Buckingham. 4. Corbus Pharmaceuticals (CRBP) coverage assumed with a Buy at Noble Financial. 5. Medpace (MEDP) initiated with a Market Perform at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/17
BARD
10/11/17
NO CHANGE
Target $69
BARD
Outperform
AnaptysBio price target raised to $69 from $36 at Baird
Baird analyst Neena Bitritto-Garg raised her price target on AnaptysBio (ANAB) to $69 from $36 following positive proof-of-concept data for its anti-IL-33 antibody, adding that its scores look more impressive than Sanofi (SNY) and Regeneron's (REGN) initial data for atopic dermatitis for Dupixent. The analyst raised her price target to reflect the strong validation of its mechanism and Bitritto-Garg reiterated her Outperform rating on AnaptysBio shares.
10/05/17
PIPR
10/05/17
NO CHANGE
PIPR
Overweight
Regeneron, Sanofi overhang removed by court ruling, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond noted that the U.S. Court of Appeals ruled in favor of Regeneron (REGN) and Sanofi (SNY) and vacated an injunction granted to Amgen (AMGN) to compel its competitors to pull Praluent from the market. While "this battle is far from over" and Raymond expects a new trial will be the next step, he also believes the ruling remove a significant marketing overhang that had hamstrung Regeneron and Sanofi sales reps. The analyst keeps an Overweight rating on Regeneron shares, which are currently halted with news pending.
09/28/17
PIPR
09/28/17
INITIATION
Target $540
PIPR
Overweight
Regeneron assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond assumed coverage of Regeneron with an Overweight rating and $540 price target. The firm previously had an Overweight rating and $557 price target on the stock.
MRK Merck

08/23/17
RAJA
08/23/17
NO CHANGE
Target $36
RAJA
Strong Buy
Paratek takeover speculation 'seems plausible,' says Raymond James
After Bloomberg reported that Paratek Pharmaceuticals (PRTK) is exploring its strategic options, including a possible sale, after receiving takeover interest, Raymond James analyst Laura Chico said she sees omadacycline as a promising asset and sees a takeout as "certainly one plausible outcome." While its "probably premature to think about a takeout price," Chico said that a possible price could arguably fall in the high-$40 to low-$50 range, adding that Merck (MRK), Pfizer (PFE) and Allergan (AGN) would all be potential buyers. She keeps a Strong Buy rating and $36 price target on Paratek shares.
09/18/17
JEFF
09/18/17
NO CHANGE
JEFF
AbbVie remains top global Pharma pick at Jefferies
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his top global pick in Pharmaceuticals, followed by Bayer (BAYRY). In the U.S., the analyst lists Zoetis (ZTS), Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) as his top picks behind AbbVie. Merck (MRK) and Novo Nordisk (NVO) are the analyst's least preferred stocks. Holford cut his price target for Underperform-rated Merck to $52 from $55 and raised his price target for Buy-rated Zoetis to $77 from $74.
09/11/17
STFL
09/11/17
NO CHANGE
Target $29
STFL
Buy
NewLink Genetics price target raised to $29 from $14 at Stifel
Stifel analyst Stephen Willey believes recently-updated melanoma data from both NewLink Genetics' (NLNK) phase 2 indoximod program and Incyte (INCY) and Merck's (MRK) ESMO presentation confirm IDO inhibitors are more-than-likely synergizing with PD-1 inhibition, adding that NewLink's drug appears to yield "slightly-better efficacy" in "slightly-healthier" patients. He increased his price target on NewLink to $29 from $14 to reflect favorable risk adjustments and higher melanoma sales estimates and keeps a Buy rating on the stock.
09/11/17
BMOC
09/11/17
NO CHANGE
BMOC
Incyte trial result 'assures commercial success,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says the results of a trial of Incyte's (INCY) epacadostat, its selective IDO1 enzyme inhibitor, in combination with Merck's (MRK) Keytruda, in patients with advanced melanoma eliminates the risk of an upcoming Phase 3 trial of epacadostat and "assures its commercial success." The analyst adds, however, that "the bar continues to be raised for IO combinations," which may make it difficult for Incyte's stock to rise in the near-term. The analyst trimmed his price target on the shares to $163 from $172 to reflect the company's capital raise. But he keeps an Outperform rating on the stock.
AMGN Amgen
$182.76

-1.39 (-0.75%)

10/05/17
BOFA
10/05/17
NO CHANGE
BOFA
Buy
Amgen price target raised to $210 at BofA/Merrill
BofA/Merrill analyst Ying Huang raised Amgen's price target to $210 to reflect the potential impact of proposed tax reform and benefits from a potential repatriation of profits. Huang rates Amgen a Buy.
10/04/17
WEDB
10/04/17
NO CHANGE
Target $37
WEDB
Outperform
CytomX Therapeutics price target raised to $37 from $26 at Wedbush
Wedbush analyst Robert Driscoll raised his price target for CytomX Therapeutics (CTMX) to $37 from $26 to reflect his increased confidence in its platform, and the extended cash runway, which the company believes to be sufficient to at least 2020. The analyst notes that the company has added Amgen (AMGN) to the Partner List with Bispecific Collaboration. He reiterates an Outperform rating on CytomX Therapeutics' shares.
10/04/17
NOMU
10/04/17
NO CHANGE
Target $44
NOMU
Buy
CytomX price target raised to $44 from $32 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target for CytomX Therapeutics (CTMX) to $44 after the company announced yesterday strategic collaboration with Amgen (AMGN) to co-develop an EGFRxCD3 Probody. The new price target incorporates potential royalties of $1.1B on sales of EGFRxCD3. The analyst keeps a Buy rating on CytomX.
ALXN Alexion
$141.46

0.23 (0.16%)

09/13/17
LEER
09/13/17
NO CHANGE
Target $182
LEER
Outperform
Alexion price target raised to $182 from $170 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Alexion to $182 from $170 on valuation. The analyst reiterates an Outperform rating on the shares.
09/14/17
LEER
09/14/17
NO CHANGE
Target $182
LEER
Outperform
Long-term follow-up confirms Alexion Soliris benefit, says Leerink
Leerink analyst Geoffrey Porges notes that Alexion announced the presentation of additional results from the open-label extension of the pivotal phase III REGAIN study of Soliris in refractory generalized myasthenia gravis. The analyst believes this longer-term follow-up analysis is highly supportive of the upcoming PDUFA on October 23. Porges reiterates an Outperform rating and $182 price target on the shares.
09/25/17
LEER
09/25/17
NO CHANGE
Target $182
LEER
Outperform
Alexion Soliris to continue dominance through 2020, says Leerink
Leerink analyst Geoffrey Porges notes that Alexion's Soliris was the first complement inhibitor to be approved by the FDA or EMA and has remained the only terminal complement inhibitor on the market. While some competitors have advanced to pivotal trials, and have established safety and efficacy, none have shown themselves to be superior to Soliris in efficacy, nor more convenient than ALXN1210, he adds. The analyst believes the development timelines for these new entrants suggest that Soliris will continue its dominance of the category through 2020, and even then will face its biggest challenge from Alexion's own next generation complement inhibitor, ALXN1210. Porges reiterates an Outperform rating and $182 price target on the shares.
09/14/17
RBCM
09/14/17
INITIATION
Target $161
RBCM
Outperform
Alexion initiated with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay initiated Alexion with an Outperform and a $161 price target saying shares are undervalued following management changes and restructuring. He said Soliris market dynamics suggest continued future growth despite PNH Patient competition.
ABBV AbbVie

10/09/17
LEER
10/09/17
NO CHANGE
LEER
Leerink not worried about JAK safety, AbbVie '494 profile so far 'ok'
Leerink analyst Geoffrey Porges notes that the delayed approval of Incyte (INCY)/Eli Lilly (LLY) baricitinib and the reported thromboembolic events in AbbVie's (ABBV) ABT494/upadacitinib trials have called into question the safety of oral Janus kinase, or JAK, inhibitors. The analyst says that his detailed review of the safety literature suggests that these medicines offer an acceptable risk/benefit profile for serious inflammatory diseases and do not confer a significant increase in cardiovascular risk or venous thromboembolic events. Further, Porges continues to believe AbbVie's upadacitinib and Gilead's (GILD) filgotinib will be approved for serious inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease, and will capture the majority share of his peak risk-adjusted $12B estimated JAK market.
10/09/17
WBLR
10/09/17
NO CHANGE
Target $110
WBLR
Outperform
AbbVie fair value estimate raised to $110 from $76 at William Blair
William Blair analyst Y. Katherine Xu raised her fair value estimate for AbbVie to $110 to reflect progress with the pipeline and the recent Humira patent victory. The analyst now models Humira to maintain U.S. patent exclusivity through the end of 2022, extended from her previous estimate of 2020. Xu believes pivotal data readouts through year-end 2017 will continue to support the outperformance of AbbVie shares. She keeps an Outperform rating on the name.
10/11/17
COWN
10/11/17
UPGRADE
Target $105
COWN
Outperform
AbbVie upgraded to Outperform from Market Perform at Cowen
Cowen analyst Steve Scala upgraded AbbVie to Outperform and raised his price target for the shares to $105 from $95. AbbVie "showed the best" of all the companies at Cowen's Annual Therapeutics Conference last week, Scala tells investors in a research note. He increased his out-year estimates for AbbVie after several of its drugs were highlighted during the conference. The stock is attractively valued versus the group overall, Scala argues.
10/11/17
10/11/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Buy from Hold at Jefferies with analyst Jeffrey Holford saying J&J's Pharma division is "under-modeled" by analysts and will drive above-consensus revenue and earnings growth. 2. Visa (V) and MasterCard (MA) were upgraded to Outperform from Market Perform at Wells Fargo. 3. Colgate-Palmolive (CL) upgraded to Buy from Hold at SunTrust with analyst William Chappell saying the recent three consecutive quarters of weak results is an "anomaly" given the company's long term track record of consistent mid-single-digit or higher organic growth. 4. AbbVie (ABBV) upgraded to Outperform from Market Perform at Cowen with analyst Steve Scala saying AbbVie "showed the best" of all the companies at Cowen's Annual Therapeutics Conference last week. 5. PayPal (PYPL) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst James Faucette calling it among the few large companies that can deliver high-teens revenue and 20% EPS growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BMY Bristol-Myers

09/15/17
DBAB
09/15/17
NO CHANGE
Target $20
DBAB
Buy
Halozyme price target raised to $20 from $17 at Deutsche Bank
Deutsche Bank analyst Andrew Peters raised his price target for Halozyme (HALO) to $20 saying he's bullish following the new Enhanze partnership. Yesterday's dual announcements for additional Enhanze collaborations are "clear positives" for the stock, Peters tells investors in a research note. He says the size of the Bristol-Myers Squibb deal, including the upfront payment, is larger than expected. The analyst reiterates a Buy rating on Halozyme.
09/15/17
JEFF
09/15/17
NO CHANGE
Target $72
JEFF
Buy
Bristol-Myers price target raised to $72 from $66 at Jefferies
Jefferies analyst Jeffrey Holford raised his price target for Bristol-Myers Squibb to $72 saying new opportunities for the Opdivo/Yervoy combo offer upside to estimates. The analyst says this, along with higher estimates for Eliquis and "significant" margin expansion over the mid term support his higher price target. Holford keeps a Buy rating on Bristol.
10/06/17
UBSW
10/06/17
NO CHANGE
Target $72
UBSW
Buy
Bristol-Myers price target raised to $72 from $62 at UBS
UBS analyst Marc Goodman raised his price target on Bristol-Myers to $72 from $62 to reflect higher product sales and flat operating expenses. The analyst also increased his sales for Opdivo given the failure of competitive drug trials and new uses for it in the head and neck setting. He believes Bristol-Myers remains the best positioned in immuno-oncology and at current prices offers a favorable risk/reward. Goodman reiterated his Buy rating on Bristol-Myers shares.

TODAY'S FREE FLY STORIES

02:45
10/17/17
10/17
02:45
10/17/17
02:45
General news
FX Update: The dollar has continued to trade perkily »

FX Update: The dollar…

20:45
10/16/17
10/16
20:45
10/16/17
20:45
General news
Breaking General news story  »

Minneapolis Federal…

20:25
10/16/17
10/16
20:25
10/16/17
20:25
Conference/Events
Federal Reserve Bank of Minneapolis participates in a dinner meeting »

Minneapolis Federal…

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

, UNH

UnitedHealth

$193.20

0.68 (0.35%)

20:25
10/16/17
10/16
20:25
10/16/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

UNH

UnitedHealth

$193.20

0.68 (0.35%)

GS

Goldman Sachs

$242.41

3.88 (1.63%)

MS

Morgan Stanley

$48.94

0.64 (1.33%)

CSX

CSX

$52.84

0.01 (0.02%)

PGR

Progressive

$48.98

0.31 (0.64%)

CMA

Comerica

$75.34

-0.21 (-0.28%)

GWW

Grainger

$182.36

1.31 (0.72%)

HOG

Harley-Davidson

$46.57

-0.05 (-0.11%)

SNV

Synovus

$46.65

0.01 (0.02%)

TTS

Tile Shop

$8.45

0.1 (1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

  • 23

    Oct

  • 27

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 15

    Nov

  • 24

    Jan

MSBI

Midland States

$33.03

-0.07 (-0.21%)

19:02
10/16/17
10/16
19:02
10/16/17
19:02
Hot Stocks
Midland States to acquire Alpine Bancorporation in roughly $181M deal »

Midland States Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 15

    Nov

MYL

Mylan

$38.18

0.23 (0.61%)

, AGN

Allergan

$198.41

-7.11 (-3.46%)

18:46
10/16/17
10/16
18:46
10/16/17
18:46
Hot Stocks
Mylan CEO: 'Pleased' with court ruling on Allergan's Restasis patents »

Mylan (MYL) announced…

MYL

Mylan

$38.18

0.23 (0.61%)

AGN

Allergan

$198.41

-7.11 (-3.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 20

    Oct

  • 23

    Oct

  • 01

    Nov

  • 06

    Nov

  • 03

    Dec

NFLX

Netflix

$202.68

3.19 (1.60%)

18:44
10/16/17
10/16
18:44
10/16/17
18:44
Hot Stocks
Netflix says seeing steady growth, great success for streaming »

Says still has bias…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 22

    Oct

PCG

PG&E

$53.43

-4.29 (-7.43%)

18:42
10/16/17
10/16
18:42
10/16/17
18:42
Hot Stocks
PG&E sees restoring service to all electric customers in CA affected by fires »

PG&E said that more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

  • 05

    Nov

  • 05

    Nov

CYTR

CytRx

$0.38

-0.0142 (-3.64%)

18:29
10/16/17
10/16
18:29
10/16/17
18:29
Hot Stocks
CytRx granted listing extension pending results of stockholder vote »

CytRx 's request for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

EADSY

Airbus

$22.75

-0.07 (-0.31%)

, BDRBF

Bombardier

$1.88

0.03 (1.62%)

18:27
10/16/17
10/16
18:27
10/16/17
18:27
Hot Stocks
Airbus and Bombardier announce C Series partnership »

Airbus (EADSY) and…

EADSY

Airbus

$22.75

-0.07 (-0.31%)

BDRBF

Bombardier

$1.88

0.03 (1.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

18:16
10/16/17
10/16
18:16
10/16/17
18:16
Conference/Events
Immune Design to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 08

    Nov

PG

Procter & Gamble

$93.14

0.1 (0.11%)

18:15
10/16/17
10/16
18:15
10/16/17
18:15
Hot Stocks
Trian: P&G board election results 'too close to call' »

Trian Fund Management,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

AMZN

Amazon.com

$1,006.34

3.4 (0.34%)

18:14
10/16/17
10/16
18:14
10/16/17
18:14
Periodicals
NJ leaders offer up to $7B in tax incentives to lure Amazon to Newark, WSJ says »

New Jersey Governor Chris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 22

    Oct

  • 26

    Oct

BDRBF

Bombardier

$1.88

0.03 (1.62%)

, EADSY

Airbus

$22.75

-0.07 (-0.31%)

18:09
10/16/17
10/16
18:09
10/16/17
18:09
Periodicals
Bombardier in talks with Airbus over CSeries jet unit JV, WSJ reports »

Bombardier (BDRBF) is in…

BDRBF

Bombardier

$1.88

0.03 (1.62%)

EADSY

Airbus

$22.75

-0.07 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:55
10/16/17
10/16
17:55
10/16/17
17:55
Hot Stocks
Impax jumps 6% in after-hours after WSJ says Amneal deal near »

Shares of Impax are up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:51
10/16/17
10/16
17:51
10/16/17
17:51
Periodicals
Impax and Amneal close to merger pact, WSJ says »

Impax Laboratories and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

AGII

Argo Group

$62.90

-0.25 (-0.40%)

17:36
10/16/17
10/16
17:36
10/16/17
17:36
Hot Stocks
Argo Group provides preliminary Q3 loss estimate »

Argo Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDEF

First Defiance Financial

$53.65

-0.25 (-0.46%)

17:34
10/16/17
10/16
17:34
10/16/17
17:34
Earnings
First Defiance Financial reports Q3 EPS 92c, consensus 89c »

Reports Q3 NII $ $25.0M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

BRO

Brown & Brown

$48.97

-0.42 (-0.85%)

17:33
10/16/17
10/16
17:33
10/16/17
17:33
Earnings
Brown & Brown reports Q3 EPS 53c, consensus 50c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

ORIG

Ocean Rig UDW

$26.18

0.51 (1.99%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
Ocean Rig holder BlueMountain intends to recommend company hire advisers »

Ocean Rig UDW holder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$202.68

3.19 (1.60%)

, IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

NFLX

Netflix

$202.68

3.19 (1.60%)

IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

SAVE

Spirit Airlines

$33.47

-0.33 (-0.98%)

UNH

UnitedHealth

$193.20

0.68 (0.35%)

BMI

Badger Meter

$50.80

-0.6 (-1.17%)

SONC

Sonic

$24.80

0.42 (1.72%)

ABEO

Abeona Therapeutics

$16.70

0.6 (3.73%)

VICL

Vical

$2.86

0.04 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

  • 23

    Oct

  • 08

    Nov

  • 17

    Oct

FDC

First Data

$18.01

0.39 (2.21%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Hot Stocks
First Data CAO sells 3,996 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

ROSG

Rosetta Genomics

$1.00

-0.0479 (-4.57%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Syndicate
Breaking Syndicate news story on Rosetta Genomics »

Rosetta Genomics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRS

Harris

$135.90

-0.66 (-0.48%)

17:27
10/16/17
10/16
17:27
10/16/17
17:27
Hot Stocks
Harris awarded $100M government contract modification »

Harris Corp., Clifton,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$259.75

-0.99 (-0.38%)

17:26
10/16/17
10/16
17:26
10/16/17
17:26
Hot Stocks
Boeing awarded $240.2M government contract »

The Boeing Co., Oklahoma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.